|
|
|
|
|
|
|
|
|
Medical Device Companies |
Diagnostic Companies | Organizations
| Search Profiles
|
Biogen Idec, Inc. (Massachusetts)
14 Cambridge Center
Cambridge
Massachusetts
02142
U.S.A.
Phone:
617-679-2000
Fax:
617-679-2617
|
Biogen Idec (NASDAQ: BIIB) is a biotechnology leader that discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. With its rich scientific heritage and passionate commitment to pioneering new advances, Biogen Idec recognizes that cutting-edge science and medicines can address unmet patient needs to change the course of devastating diseases.
Founded in 1978, Biogen Idec is the world’s oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies, and the company generates nearly $5 billion in annual revenues. Biogen Idec has a strong late stage pipeline with the potential to launch new products for multiple sclerosis, amyotrophic lateral sclerosis (ALS) and hemophilia by 2015.
With about 4,800 employees worldwide, Biogen Idec is a truly global organization. In addition to our headquarters in Weston, Mass., and our research operations in Cambridge, Mass., we have a world-class manufacturing facility in North Carolina and offices in Canada, Australia, Japan and throughout Europe. We also have a direct commercial presence in more than 29 markets and a network of distribution partners in more than 70 additional markets, including new markets such as Central/Eastern Europe, Brazil, China and India.
For product labeling, press releases and additional information about the company, please visit www.biogenidec.com
Email:
Ownership:
Public
Web Site:
Biogen Idec, Inc. (Massachusetts)
Employees:
1700
Symbol: BIIB
|
|
|
Company News |
Biogen Idec, Inc. (Massachusetts) (BIIB) 2013 Annual Shareholder Meeting Webcast
6/5/2013 6:58:10 AM
More...
|
Will Data Exclusivity Issues Blunt Biogen Idec, Inc. (Massachusetts) (BIIB)'s Assault on the European Oral MS Market?
6/4/2013 8:32:56 AM
More...
|
Biogen Idec, Inc. (Massachusetts) (BIIB)'s MS Drug Launch Going Amazingly Well
5/30/2013 8:14:31 AM
More...
|
Biogen Idec, Inc. (Massachusetts) (BIIB) to Present at the Jefferies and Co. 2013 Global Healthcare Conference
5/29/2013 7:24:55 AM
More...
|
MS Patients Choose Death Risk With Biogen Idec, Inc. (Massachusetts) (BIIB)'s Potent Drug Treatment
5/23/2013 8:26:23 AM
More...
|
Biogen Idec, Inc. (Massachusetts) (BIIB) Appoints Spyros Artavanis-Tsakonas Chief Scientific Officer
5/23/2013 7:54:15 AM
More...
|
Biogen Idec, Inc. (Massachusetts) (BIIB) to Present at the Deutsche Bank (DB) 38th Annual dbAccess Healthcare Conference
5/23/2013 7:29:23 AM
More...
|
Biogen Idec, Inc. (Massachusetts) (BIIB) Submits Application to FDA for Approval of PLEGRIDY™ (Peginterferon Beta-1a) in Multiple Sclerosis
5/21/2013 11:32:42 AM
More...
|
Genentech (RHHBY) and Biogen Idec, Inc. (Massachusetts) (BIIB) Have Filed for a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case
5/17/2013 9:13:20 AM
More...
|
FDA Accepts Biogen Idec, Inc. (Massachusetts) (BIIB)’s Biologics License Application for First Long-Lasting Factor VIII Therapy for Hemophilia A
5/13/2013 11:06:30 AM
More...
|
|
|
|
 |
|
|
|
|
|
|
|
|